M. Tabart

发表

1.2 Importance of Chirality in the Field of Anti-infective Agents

D. Lesuisse, M. Tabart, 2012 .

The use of N-sulfenylimines in the β-lactam synthon method: Staudinger reaction, oxidation of the cycloadducts and ring opening of β-lactams

S. Mignani, M. Tabart, Stéphanie Coantic, 2007 .

Synthesis and biological evaluation of benzo[b]naphthyridones, a series of new topical antibacterial agents.

S. Dutka-Malen, M. Tabart, N. Berthaud, 2001, Bioorganic & medicinal chemistry letters.

Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.

S. Dutka-Malen, M. Tabart, J. Malleron, 2003, Bioorganic & medicinal chemistry letters.

Synthesis of RPR 100893, prototype of a new series of potent and selective non peptide NK1 antagonists : the triarylperhydroisoindolols.

M. Tabart, J. Peyronel, 1994 .

Stereoselective synthesis of trans-disubstituted-β-lactams from N-phenylsulfenylimines

S. Mignani, M. Tabart, Stéphanie Coantic, 2007 .

Synthesis and structure-activity relationships in perhydroisoindole substance P antagonists

M. Tabart, J. Malleron, J. Peyronel, 1995 .

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.

S. Gross, Q. Gao, D. Wiederschain, 2014, Blood.

suppression of STAT 5 activation and degradation of MYC oncogene PIM inhibitors target CD 25-positive AML cells through concomitant

S. Gross, Q. Gao, D. Wiederschain, 2014 .

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

D. Wiederschain, C. García-echeverría, C. Lengauer, 2014, Oncotarget.

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, C. García-echeverría, L. Debussche, 2020, Molecular Cancer Therapeutics.

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, L. Debussche, M. Levit, 2020 .

Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel

Jiesheng Kang, D. Rampe, M. Tabart, 2005, Molecular Pharmacology.

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

M. Mathieu, C. García-echeverría, M. Levit, 2019, Journal of medicinal chemistry.